- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07598708
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared With Placebo in Participants With Central Disorders of Hypersomnolence
Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness [EDS]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.
While all conditions result in feeling sleepy, there are some differences in other common symptoms:
- NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.
- NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.
Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The SAPPHIRE Clinical Trial
The Sponsor may in the future, through a protocol amendment, expand the protocol to include participants with idiopathic hypersomnia (IH) in Cohort C.
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Centessa Pharmaceuticals
- Telefonnummer: 617-468-5770
- E-post: ORX750trials@centessa.com
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35213
- Rekruttering
- Birmingham, Alabama
-
-
Colorado
-
Colorado Springs, Colorado, Forente stater, 80918
- Rekruttering
- Colorado Springs, Colorado
-
-
Florida
-
Brandon, Florida, Forente stater, 33511
- Rekruttering
- Brandon, Florida
-
Miami, Florida, Forente stater, 33155
- Rekruttering
- Miami, Florida
-
Miami, Florida, Forente stater, 33176
- Rekruttering
- Miami, Florida
-
Miami, Florida, Forente stater, 33166
- Rekruttering
- Miami, Florida
-
Miami, Florida, Forente stater, 33186
- Rekruttering
- Miami, Florida
-
Miami Lakes, Florida, Forente stater, 33014
- Rekruttering
- Miami Lakes, Florida
-
Orlando, Florida, Forente stater, 32807
- Rekruttering
- Orlando, Florida
-
St. Petersburg, Florida, Forente stater, 33707
- Rekruttering
- St. Petersburg, Florida
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30328
- Rekruttering
- Atlanta, Georgia
-
Rincon, Georgia, Forente stater, 31326
- Rekruttering
- Rincon, Georgia
-
Stockbridge, Georgia, Forente stater, 30281
- Rekruttering
- Stockbridge, Georgia
-
-
Michigan
-
Lansing, Michigan, Forente stater, 48911
- Rekruttering
- Lansing, Michigan
-
-
Mississippi
-
Flowood, Mississippi, Forente stater, 39232
- Rekruttering
- Flowood Mississippi
-
-
North Carolina
-
Denver, North Carolina, Forente stater, 28037
- Rekruttering
- Denver, North Carolina
-
Huntersville, North Carolina, Forente stater, 28078
- Rekruttering
- Huntersville, North Carolina
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45245
- Rekruttering
- Cincinnati, Ohio
-
Dublin, Ohio, Forente stater, 43017
- Rekruttering
- Dublin, Ohio
-
-
South Carolina
-
Columbia, South Carolina, Forente stater, 29201
- Rekruttering
- Columbia, South Carolina
-
-
Texas
-
Austin, Texas, Forente stater, 78731
- Rekruttering
- Austin, Texas
-
Dallas, Texas, Forente stater, 75251
- Rekruttering
- Dallas, Texas
-
Frisco, Texas, Forente stater, 75033
- Rekruttering
- Frisco, Texas
-
Houston, Texas, Forente stater, 77070
- Rekruttering
- Houston, Texas
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- San Antonio, Texas
-
Sugar Land, Texas, Forente stater, 77478
- Rekruttering
- Sugar Land, Texas
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- 18-70 years of age
- Body Mass Index (BMI) within the range ≥ 17.0 and ≤ 45 kg/m^2 (inclusive)
- Meets the diagnostic criteria of Narcolepsy Type 1 (NT1) or Type 2 (NT2) according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD-3-TR) criteria
- Is willing and able to discontinue all medications used for the treatment of narcolepsy
- Is willing and able to adhere to additional protocol requirements
Key Exclusion Criteria:
- Medical disorder other than NT1 or NT2, that is associated with excessive daytime sleepiness (EDS)
- Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Group A - Narcolepsy Type 1 (Dose 1)
|
Oral cleminorexton capsule |
|
Eksperimentell: Group A - Narcolepsy Type 1 (Dose 2)
|
Oral cleminorexton capsule |
|
Placebo komparator: Group A - Narcolepsy Type 1 (placebo)
|
matching placebo capsule |
|
Eksperimentell: Group B - Narcolepsy Type 2 (Dose 1)
|
Oral cleminorexton capsule |
|
Eksperimentell: Group B - Narcolepsy Type 2 (Dose 2)
|
Oral cleminorexton capsule |
|
Placebo komparator: Group B - Narcolepsy Type 2 (placebo)
|
matching placebo capsule |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT)
Tidsramme: Baseline to week 12
|
Baseline to week 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in Epworth Sleepiness Scale (ESS) total score
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Incidence, Severity, and casual relationship of participants with Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in clinical laboratory tests
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in vital signs
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in 12-lead electrocardiograms (ECGs)
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with at least 1 endorsement of Item 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Cmax: Maximum observed plasma concentration
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Tmax: Time of Maximum Concentration for cleminorexton
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
AUC: Area under the plasma concentration-time curve
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Weekly Cataplexy Rate (WCR)
Tidsramme: Week 12
|
Measurement specific to Group A |
Week 12
|
|
Change from baseline in Narcolepsy Severity Scale for Clinical Trials (NSS-CT)
Tidsramme: Baseline to Week 12
|
Measurement specific to Group A |
Baseline to Week 12
|
|
Change from baseline in Narcolepsy Severity Scale-2 for Clinical Trials (NSS2-CT) total score
Tidsramme: Baseline to Week 12
|
Measurement specific to Group B |
Baseline to Week 12
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- SAFIR
- Sykdommer i nervesystemet
- Sove
- Søvnforstyrrelse
- Søvnighet
- Psykiske lidelser
- Orexin
- Forstyrrelser av overdreven somnolens
- Narkolepsi
- Overdreven søvnighet på dagtid
- Katapleksi
- Dyssomnier
- Søvnvåkenforstyrrelser
- Hypersomni
- Narkolepsi type 1
- Narkolepsi type 2
- NT2
- NT1
- Orexin reseptor 2 agonist
- Hypersomnolens
- Central Disorders of Hypersomnia
- ORX750
- Cleminorexton
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ORX750-004
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .